Table 4. The significant factors associated with the survival of NPC patients identified in a multivariate analysis that included the tumor CTLA-4 expression.
| Characteristics | OS | FFS | D-FFS | LR-FFS | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | |
| Tumor CTLA-4 | 2.069 | 0.929–4.606 | 0.075 | 1.769 | 0.964–3.247 | 0.066 | 1.992 | 1.020–3.891 | 0.044 | * | ||
| BMI | 0.762 | 0.661–0.879 | 0.000 | 0.914 | 0.828–1.008 | 0.071 | * | 0.819 | 0.665–1.008 | 0.059 | ||
| UICC stage | 1.765 | 1.057–2.948 | 0.030 | 5.207 | 2.849–9.518 | 0.000 | 6.528 | 3.370–12.649 | 0.000 | 2.029 | 0.906–4.544 | 0.085 |
| CRP | 1.047 | 1.020–1.075 | 0.001 | 1.027 | 1.004–1.050 | 0.022 | 1.032 | 1.009–1.055 | 0.005 | * | ||
Abbreviations: OS, overall survival; FFS, failure free survival; D-FFS, distant failure-free survival; LR-FFS, localregional failure-free survival.* Not a significant factor.